Source: Annual Congress 2009 - Sarcoidosis and profiles of other diffuse parenchymal lung disease
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Stacher, J. Loeffler-Ragg, J. Guenther, K. Cima, S. Desole, H. H. Popper, C. M. Kähler (Graz, Innsbruck, Austria). Expression of potential therapeutic targets in pulmonary Langerhans´ cell histiocytosis. Eur Respir J 2009; 34: Suppl. 53, 3124

Member's Comments

No comment yet.

Related content which might interest you: Drug target expression in pulmonary langerhans´cell histiocytosis Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Adult pulmonary Langerhans‘ cell histiocytosis and lung cancer Source: Annual Congress 2009 - Clinical aspects and epidemiology in lung cancer Year: 2009 A role for ITPA variants in the clinical course of pulmonary Langerhans' cell histiocytosis? Source: Eur Respir J 2010; 36: 684-686 Year: 2010 Effect of cladribine therapy on lung cysts in pulmonary Langerhans cell histiocytosis Source: ERJ Open Res, 4 (1) 00089-2017; 10.1183/23120541.00089-2017 Year: 2018 Clinical and pathological features of 13 adult patients with pulmonary Langerhans‘ cell histiocytosis Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009 Genetic landscape of pulmonary langerhans cell histiocytosis Source: International Congress 2018 – Progress in rare interstitial lung diseases Year: 2018 Clinical impact of BRAFV600E mutation in adult pulmonary Langerhans cell histiocytosis Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases Year: 2019 Pulmonary Langerhans cell histiocytosis – analysis of factors influencing the course of the disease Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009 Exercise in patients with pulmonary Langerhans cell histiocytosis: performance and mechanisms of limitation Source: International Congress 2017 – From idiopathic pulmonary fibrosis (IPF) to rare diseases Year: 2017 Langerhans' cell histiocytosis: clinical and diagnostic features and response to therapy Source: Eur Respir J 2001; 18: Suppl. 33, 219s Year: 2001 Gene expression profiles of idiopathic interstitial pneumonias: Identification of disease-specific diagnostic markers and molecular therapeutic targets Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Pulmonary hypertension in pulmonary Langerhans’ cell histiocytosis Source: Eur Respir Mon 2012; 57: 161-165 Year: 2012 Fibrocytes: potential new therapeutic targets for pulmonary hypertension? Source: Eur Respir J 2010; 36: 1232-1235 Year: 2010 Oral presentation: Human lung parenchyma cells: a potential therapeutic cell source for lung disease Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis Year: 2009 Genetic landscape of adult Langerhans cell histiocytosis with lung involvement Source: Eur Respir J, 55 (2) 1901190; 10.1183/13993003.01190-2019 Year: 2020 Pulmonary Langerhans‘ cell histiocytosis (PLCH): A new UK register Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis Year: 2012 Pulmonary Langerhans' cell histiocytosis Source: Respipedia Article Year: 2016 Clinical features and outcome of adult patients with pulmonary Langerhans cell histiocytosis Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases Year: 2019 Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis Source: Eur Respir J 2016; 47:1785-1796 Year: 2016